The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.75
Bid: 32.50
Ask: 33.00
Change: 0.25 (0.76%)
Spread: 0.50 (1.538%)
Open: 32.75
High: 33.50
Low: 33.00
Prev. Close: 32.75
DUKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

11 Apr 2022 07:00

RNS Number : 8761H
Duke Royalty Limited
11 April 2022
 

11 April 2022

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

Trading Update

 

Duke Royalty, a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and North America, is pleased to provide the following trading update for its fourth financial quarter ended 31 March 2022 ("Q4 FY22"), and to provide guidance on trading for the first quarter of the Company's 2023 financial year, ending 30 June 2022 ("Q1 FY23").

Financial Highlights:

Q4 FY22 represented a record quarter of cash generation in the Company's five-year operating history, both in terms of total cash revenue* and normalised cash revenue**  Total cash revenue was £6.7 million, representing a 37% increase over the previous record quarterly flows in Q2 FY22 of £4.9 million Normalised cash revenue totalled £4.7 million, an increase of 21% on the previous quarter and an 88% increase over Q4 FY21 Following the Company's £5.3 million follow-on investment into Miriad Products ("Miriad") in December 2021, Miriad completed its shareholder restructure in Q4 FY22, realising £1.9 million of cash proceeds to Duke whilst still retaining its 30% equity stake in the business Duke Royalty's last four quarters of Normalised Cash Revenue and Total Cash Revenue are as follows: 

-

Normalised Cash Revenue**

Total Cash Revenue*

Q1 FY22

£2.9 million

£2.9 million

Q2 FY22

£3.3 million

£4.9 million

Q3 FY22

£3.9 million

£3.9 million

Q4 FY22

£4.7 million

£6.7 million

 

* Total cash revenue is monthly cash distributions from Duke's royalty partners plus cash gains received from the sales of equity assets and redemption premiums

** Normalised cash revenue excludes redemption premium receipts and cash gains from equity sales

 

Based on current trading, Duke expects Q1 FY23 normalised cash revenue to be £5.0 million 

Capital Deployments:

During Q4 FY22, Duke committed a further £13.3m of investment to support the "buy and build" strategies of four of its current royalty partners. This was made up of five separate follow-on transactions as follows: 

 -

Two investments into InTec Business Solutions Limited of £2.45 million in January and £1.65 million in February to finance the acquisitions of Provident Technology Limited, Firefly Enterprises Limited and Opal IT Limited, respectively

 -

A £1.5 million investment into Lynx Equity (UK) Ltd to facilitate their acquisition of Obel-P Automation A/S

 -

A £1.55 million investment into Tristone Healthcare Limited to finance its acquisition of Seaside Care Homes Limited

 -

A CA$10.3 million (£6.2 million) investment into Creō-Tech Industrial Group Inc, facilitating the purchase of California-based MD Stainless Services

 Other Q4 Highlights

A second consecutive quarterly dividend rise, increasing 17% from 0.60 pence per quarter to 0.70 pence Drew down the £20 million accordion facility with Honeycomb Investment Trust, unlocking additional liquidity Cash receipt of €4 million from the early repayment of the 2nd tranche of deferred consideration relating to the sale of Duke's three European river cruise vessels. This amount had originally been due for repayment by 30 September 2022. Currently only €2.6 million remains outstanding and due for repayment on or before 30 June 2023 

Neil Johnson, CEO of Duke Royalty, said:

"It is pleasing to report that normalised cash revenue has continued to grow, with Q4 FY22 representing the sixth consecutive quarterly cash revenue increase since the initial impact of Covid. Given Duke's largely fixed cost base, the recent acceleration in deployments has led to a material increase in cashflow per share and we are delighted to be able to share this operational leverage with our shareholders through increasing the quarterly dividend which has risen 27% in the last year.

"We continue to see a strong pipeline of royalty opportunities to service both existing and new companies. Despite the macroeconomic and geopolitical headwinds, our portfolio as a whole continues to perform well. The resilience demonstrated is a benefit of our exposure to a range of underlying companies across diverse geographies and sectors."

***ENDS***

 

For further information, please visit www.dukeroyalty.com or contact:

 

 

Duke Royalty Limited

Neil Johnson / Charles Cannon Brookes / Hugo Evans

 

 

+44 (0) 1481 730 613

Cenkos Securities plc 
(Nominated Adviser
and Joint Broker)
 
Stephen Keys / Callum Davidson / Michael Johnson

 

+44 (0) 207 397 8900

 

Canaccord Genuity

(Joint Broker)

 

Adam James / Georgina McCooke

 

 

+44 (0) 207 523 8000

SEC Newgate (PR)

Elisabeth Cowell / Richard Bicknell / Max Richardson

 

+44 (0) 20 3757 6882 dukeroyalty@secnewgate.co.uk

 

About Duke Royalty

 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFLTSIIILIF
Date   Source Headline
30th Aug 20223:07 pmRNSHolding(s) in Company
5th Aug 20227:00 amRNSNotice of Results and Presentations
4th Aug 20227:00 amRNSTrading Update
21st Jun 20227:00 amRNSInterim Dividend and Dividend Declaration
1st Jun 20224:25 pmRNSHolding(s) in Company
27th May 20229:08 amRNSDirector / PCA Dealings
26th May 20223:23 pmRNSResult of General Meeting and Issue of Equity
11th May 20227:05 amRNSRaises £20m through Placing and PrimaryBid Offer
10th May 20225:08 pmRNSPrimaryBid Offer
10th May 20224:44 pmRNSPlacing to raise a minimum of £15 million
28th Apr 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
20th Apr 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
11th Apr 20227:00 amRNSTrading Update
18th Mar 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
17th Mar 20227:00 amRNSIncreased Interim Dividend & Dividend Declaration
2nd Mar 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
25th Feb 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
17th Feb 20227:00 amRNSFurther re: Directorate Change
14th Feb 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
2nd Feb 20227:00 amRNSDirectorate Changes
1st Feb 202210:02 amRNSReplacement - Trading Update
1st Feb 20227:00 amRNSTrading Update
20th Jan 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
23rd Dec 20212:30 pmRNSHolding(s) in Company
23rd Dec 20217:01 amRNSTrading Update
23rd Dec 20217:00 amRNSFollow-on investment into existing Royalty Partner
22nd Dec 20213:52 pmRNSFollow-on investment into existing Royalty Partner
16th Dec 20217:00 amRNSNew Royalty Agreement
14th Dec 20217:00 amRNSIncreased Interim Dividend & Dividend Declaration
7th Dec 20217:00 amRNSEnters into Largest Royalty Agreement To Date
3rd Dec 20217:00 amRNSInterim Results
2nd Dec 20217:00 amRNSCompletion of £4.2 million Follow-On Investment
25th Nov 20217:00 amRNSNotice of Interim Results
29th Oct 20214:03 pmRNSLong Term Incentive Plan Awards
27th Oct 20217:01 amRNSFollow-On Investment into Existing Royalty Partner
27th Oct 20217:00 amRNSHolding(s) in Company
22nd Oct 20214:36 pmRNSResult of Annual General Meeting
16th Sep 20217:01 amRNSInterim Dividend and Dividend Declaration
16th Sep 20217:00 amRNSFinal Results
7th Sep 20217:00 amRNS£2.2m Follow-On Investment into Royalty Partner
2nd Sep 20217:00 amRNSHolding(s) in Company
17th Aug 20217:00 amRNSInvestor Presentation
11th Aug 20217:00 amRNSSuccessful Exit of Investment in Royalty Partner
10th Aug 20217:00 amRNSNotice of Results and Analyst Presentation
2nd Aug 20217:00 amRNSNew Royalty Agreement
26th Jul 20217:00 amRNSTrading Update
22nd Jul 20217:00 amRNSNew Royalty Agreement
1st Jul 20217:00 amRNSNew Royalty Agreement with Fairmed Healthcare AG
17th Jun 20217:00 amRNSInterim Dividend and Dividend Declaration
10th May 20217:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.